Full Approval for a Bladder Cancer Treatment
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved...
Progress Against Cancer
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved...
Belzutifan is now available for certain patients with kidney cancer whether or not they have von Hippel-Lindau disease. The...
The FDA has approved eflornithine to prevent relapse after standard-of-care therapy for neuroblastoma. The U.S. Food and Drug Administration...
The FDA has approved pirtobrutinib for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The U.S....
The FDA has approved nirogacestat for the treatment of noncancerous but painful growths called desmoid tumors. The U.S. Food...
The FDA has approved enzalutamide for non-metastatic prostate cancer that is sensitive to antiandrogen therapy. The U.S. Food and...
The FDA has approved capivasertib for the treatment of breast cancers with certain mutations. The U.S. Food and Drug...
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S....
The FDA has approved repotrectinib for certain patients with non-small cell lung cancer harboring a ROS1 mutation or rearrangement. ...
The FDA has approved another inhibitor of the VEGF receptor family for patients with metastatic, heavily pretreated colorectal cancer. ...